Key Highlights

  • Stereotaxis (NYSEAMERICAN:STXS) rose 11.86% to USD 0.943, after Robocath reported 100% clinical success in 20 of 20 patients.
  • Imunon (NASDAQ:IMNN) gained 8.89% to USD 0.98, with no new announcement identified and cash of USD 6.9 million at June 30, 2026.
  • 20/20 Biolabs (NASDAQ:AIDX) advanced 14.77% to USD 0.2696, ahead of a noon Eastern investor webinar on OneTest.
  • Nuwellis (NASDAQ:NUWE) slipped 11.34% to USD 5.24, following a recent reverse stock split.
  • RxSight (NASDAQ:RXST) dropped 9.59% to USD 4.15, after third quarter Revenue fell 19% to USD 24.6 million.

Stereotaxis (NYSEAMERICAN:STXS) (up USD 0.1000, 11.86%): Robotic Heart Study Gets Attention

Stereotaxis (NYSEAMERICAN:STXS) climbed 11.86% to USD 0.943 in pre-market trading on November 4, 2026, a gain of USD 0.1000 from a Tuesday close of about USD 0.843 (calculated). A company release dated November 2, 2026 described first-in-human results for the next-generation robotic system from its Robocath subsidiary.

The study involved 20 patients, with clinical success of 100% (20 of 20) and technical success of 95%. No major adverse events were reported through 30 days. The company has not linked the share move to the release, so that timing link is an inference. The sample is small and has no comparator group, and as a Penny Stock the shares carry Volatility and dilution risk.

Imunon (NASDAQ:IMNN) (up USD 0.0800, 8.89%): Low-Priced Biotech Gains With No New Release

Imunon (NASDAQ:IMNN) rose 8.89% to USD 0.98 in pre-market trading on November 4, 2026, which implies a Tuesday close of about USD 0.90 (calculated). No company release, filing or trial readout dated November 3 or November 4, 2026 was identified, so the gain appears to reflect trading momentum in a low-priced clinical-stage biotech.

The lead candidate, IMNN-001, is in the Phase 3 OVATION 3 trial for newly diagnosed advanced ovarian cancer. The second quarter 2026 net loss was USD 2.8 million, and cash of USD 6.9 million at June 30, 2026 compares with USD 7.0 million used in operations over six months, a short funding horizon on a calculated reading. A planned stock split with no stated ratio adds dilution and price risk.

20/20 Biolabs (NASDAQ:AIDX) (up USD 0.0347, 14.77%): Investor Webinar Day for a Low-Priced Stock

20/20 Biolabs (NASDAQ:AIDX) climbed 14.77% to USD 0.2696 in pre-market trading on November 4, 2026. No Earnings or financing announcement dated November 2 to November 4 was identified. The company holds an investor webinar at 12:00 p.m. Eastern the same day, covering OneTest, licensing and FDA strategy, and it does not cover third quarter results.

Second quarter 2026 revenue was USD 730,571, up 36.5%, while the net loss was USD 1,506,343. Common shares outstanding more than doubled to 12,251,198 from 5,442,249 (calculated dilution above 125%). Stockholders' Equity of USD 1,620,700 sits below the USD 2,500,000 Nasdaq minimum, a shortfall of USD 879,300 (calculated).

Nuwellis (NASDAQ:NUWE) (down USD 0.6702, 11.34%): Surrendering Gains After a Reverse Split

Nuwellis (NASDAQ:NUWE) fell 11.34% to USD 5.24 in pre-market trading on November 4, 2026, from a Tuesday close of USD 5.91. No company announcement dated November 3 or November 4 was identified. A plausible backdrop is profit-taking after a sharp run that followed the reverse stock split, with split-adjusted trading set to begin on October 27, 2026.

Second quarter 2026 revenue was USD 1.97 million, up about 14%. Cash was about USD 3.9 million at June 30, with about USD 3.4 million more from a registered direct offering and about USD 3.3 million from Warrant exercises raised afterward. The filing included Going Concern language, so dilution remains possible.

RxSight (NASDAQ:RXST) (down USD 0.4402, 9.59%): Weak Quarter Weighs on a Stock Under USD 5

RxSight (NASDAQ:RXST) fell 9.59% to USD 4.15 in pre-market trading on November 4, 2026, from an implied Tuesday close of about USD 4.59 (calculated from published market data). The move came after third quarter results released on November 3.

Revenue fell 19% to USD 24.6 million from USD 30.3 million, gross Margin was 73.6% against 79.9%, and the net loss widened to USD 16.2 million from USD 9.8 million. No financial guidance was given, although management expects fourth quarter lens sales to rise by mid to high single digits sequentially. Cash was USD 254.7 million, but the company carries a USD 50.0 million refund liability, and below USD 5 the penny stock can be volatile with limited liquidity.

Where Things Stand

The five names share a medical technology or diagnostics label but move for different reasons. Stereotaxis has a small study and an earnings date, AIDX has a webinar and listing issues, RxSight has a reported earnings decline, while Imunon and Nuwellis moved without an identified announcement. Watch Stereotaxis results on November 10, the AIDX webinar remarks, third quarter reports from Imunon and Nuwellis, and RxSight's fourth quarter lens volume.